A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of CM313 in the treatment of immune thrombocytopenia in
patients who have not responded adequately or relapsed after first-line treatment and at
least one second-line therapy including rituximab and/or TPO-RA.